France-based cancer centre Gustave Roussy has expanded its partnership with healthcare software company Sophia Genetics.

Specialised in treating various cancer types including rare and complex tumours, Gustave Roussy will use SOPHiA GENETICS' SOPHiA DDM Platform for accelerated analysis and insights from genomic profiles.

This expansion builds on their collaboration since 2017 and aims to expedite cancer treatment plan development by interpreting large datasets.

The platform integration involves updating Gustave Roussy's database and laboratory systems for improved precision medicine and data-driven diagnostics.

According to SOPHiA GENETICS, its SOPHiA DDM Platform leverages AI capabilities to standardise, compute, and analyse digital health data from complex multimodal datasets.

This is said to enhance accuracy and quality, particularly for challenging data modalities.

The platform fosters decentralised digital health data analytics, connecting global healthcare institutions to promote collaborative research.

As the platform accumulates more data, it evolves into a collective intelligence that aids research, diagnosis, treatment selection, and drug development.

The modular design supports analysis for specific data types and use cases.

Gustave Roussy genetics unit head Etienne Rouleau said: “With the rapidly evolving field of clinical genomics, the challenges of data analysis are now twofold – the ability to meet the production quality requirements, which are becoming more and more stringent with the IVDR regulations, and the ability to innovate with the arrival of new genomic signatures and techniques.

“The SOPHiA DDM Platform, a recognised solution in terms of quality – ISO13485 and ISO27001 – and performance, was the optimal solution for Gustave Roussy.”

SOPHiA GENETICS promotes data-driven medicine across healthcare and life sciences through its cloud-native platform and associated solutions, serving hospital, laboratory, and biopharma institutions.